University of California starts its fightback against rival Broad Institute in their dispute over intellectual property for CRISPR-Cas9.

The decision follows a review that foresaw bleak prospects for the program and little reason to invest in its development.

Canaan will continuw the strategy that has delivered it paydays as companies including J&J and Teva have snapped up pieces of its portfolio.

Get Tuesday's shot of biopharma news of note.

The series B equips the biotech to take its lead treatment for multidrug-resistant Gram‐negative infections through clinical trials.

The Big Pharma wants to offload six phase 2 candidates to focus its R&D dollars on a clutch of early to midstage assets.

Rodeo has got off a $5.9 million series A financing round with a list of all-stars as backers.

Monday's dose of FierceBiotech's news of note.

A multipronged immune attack that includes CAR-T treatments may be needed to fight glioblastoma, Penn scientists suggest.